Research on Reimbursement Management of Innovative Drugs Abroad and Its Enlightenment to China

Abstract

Objective To analyze the reimbursement policies of innovative drugs in some developed countries, and to provide reference for future reimbursement management in China. Methods Literature research method was used to study the policies related to the reimbursement management of innovative drugs in Germany, France and Japan, and their successful experience was summarized. Results and Conclusion China should establish an open and transparent value evaluation standard to improve the medical insurance reimbursement management of innovative drugs. Besides, the value of innovative drugs should be taken as an important basis for reimbursement decisions, and an independent third-party value evaluation agency must be established.

Keywords

innovative drug / medical insurance / reimbursement

References

[1] National Medical Products Administration. Measures for the Administration of Drug Registration[EB/OL]. (2020-03-30)[2022-03-09]. https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20200330180501220.html.

[2] National Bureau of Statistics of the People’s Republic of China. Urban basic medical insurance[EB/OL]. [2022-03-09]. https://data.stats.gov.cn/easyquery.htm?cn=C01.

[3] Zhu Hengpeng. Give full play to the strategic purchasing role of medical insurance funds to promote the high-quality coordinated development of medical insurance and medical services[J]. China Health Insurance, 2020 (2):4-6.

[4] Garattini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis[J]. Health Policy, 2007, 82 (3): 330-339.

[5] Zhao Huating, Yan Jianzhou, Shao Rong. Enlightenment of German clinical benefit evaluation on the clinical value evaluation of my country’s innovative drug medical insurance access[J]. Chinese Journal of New Drugs, 2019, 28 (19): 2323-2326.

[6] IQWiG. Allgemeine Method Version 6.1[EB/OL]. (2022-01-24)[2022-03-14]. https://www.iqwig.de/methoden/allgemeine-methoden-v6-1.pdf.

[7] Zhang Yuli, Xu Ruihong, Wu Jing. Rules and procedures for the formulation of medical insurance payment standards for newly marketed drugs in Germany[J]. China Journal of Pharmaceutical Economics, 2018, 13 (2): 31-33+41.

[8] Shen Qiuhuan. Drug reference price system typical national innovative drug pricing and compensation mechanism[J]. Chinese Journal of New Drugs, 2017, 26 (14): 1612-1617.

[9] HAS. Évaluation Des Médicaments-Doctrine de La Commission de La Transparence -principes d’évaluation de la CT relatifs aux médicaments en vue de leur accès au remboursement[EB/OL]. (2020-12-02)[2021-03-08]. https://www.has-Sante.fr/upload/docs/application/pdf/2021-03/doctrine_ct.pdf.

[10] Lu Bixiang, Guan Yiru, Zhang Fang. Management of clinical efficacy and improvement of clinical efficacy of drugs in France and its inspiration[J]. Chinese Journal of Drug Application and Monitoring, 2018, 15 (2): 113-117.

[11] Franken M, Stolk E, Scharringhausen T, et al. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries[J]. Health Policy, 2015, 119 (2): 195-202.

[12] Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: Implications for key stakeholder groups[J]. Applied Health Economics And Health Policy, 2010, 8 (1): 7-24.

[13] Wang Liang, Li Aihua, Yue Xiaomeng, et al. Research on Japan’s drug price system and its enlightenment to China’s drug price management[J]. Chinese Health Economics, 2017, 36 (10): 87-91.

[14] Shiroiwa T, Fukuda T, Ikeda S, et al. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations[J]. Health Policy, 2017, 121 (8): 836-841.